[
    [
        {
            "time": "2018-05-06",
            "original_text": "Top Ranked Income Stocks to Buy for May 6th",
            "features": {
                "keywords": [
                    "Ranked",
                    "Income",
                    "Stocks",
                    "Buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Top Ranked Income Stocks to Buy for May 6th",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-06",
            "original_text": "The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Merck",
                    "Pfizer",
                    "AbbVie",
                    "Sanofi",
                    "Glaxo"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-06",
            "original_text": "Two Healthcare Stocks in the XLV Fund Stand Out",
            "features": {
                "keywords": [
                    "Healthcare",
                    "XLV",
                    "Fund",
                    "Stand",
                    "Out"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Two Healthcare Stocks in the XLV Fund Stand Out",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-06",
            "original_text": "Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002",
            "features": {
                "keywords": [
                    "Alector",
                    "Alzheimer’s",
                    "Disease",
                    "Patient",
                    "Phase",
                    "1b",
                    "Study",
                    "AL002"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]